Skip to content
No results
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx

Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer?

April 10, 2017

Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer?

Journal of Gastrointestinal Cancer and Stromal Tumors – April 2017

JGCST-02-114

Share This Post

XFacebookLinkedInMessengerWhatsApp

Posts navigation

← Celleron Therapeutics announces completion of a new funding round with international investors
CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research →

More Posts

Interim Phase 2 Results Suggest Zabadinostat Combination Improves Overall Survival in Advanced Liver Cancer

February 26, 2025

IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation

February 10, 2025

IngenOx Therapeutics CMO Receives China Friendship Medal

October 21, 2024
IngenOx

  • Registered Address: Magdalen Centre Oxford Science Park Robert Robinson Avenue Oxford, OX4 4GA
  • Email: enquiries@ingenOx.com

Products

  • Zabadinostat (CXD101)
  • PRMT5 Inhibitor (AT101)
  • Cancer Vaccine (PCV001)
  • Pipeline

About Us

  • About
  • Executive Team
  • Board of Directors
  • Strategic Collaborations

Useful Links

  • Careers
  • Press Releases
  • Publications
  • Contact

Copyright © 2025 

  • Anti-Slavery Statement
  • Privacy Statement